Mahana Therapeutics, a prominent provider of prescription digital therapeutics, unveiled significant results from an analysis presented by Dr. Mythili Pathipati of Mass General Hospital at the ACG 2023 Scientific Meeting in Vancouver. The findings revealed that nearly 60% of users who completed the Mahana IBS program in real-world settings experienced a notable reduction in the severity of their IBS symptoms. Additionally, the use of Mahana IBS considerably alleviated stress, as gauged by the Perceived Stress Scale (PSS). The study also identified key demographics that would most likely adhere to and benefit from the Mahana IBS program.
The real-world analysis assessed the outcomes from 843 patients using Mahana IBS over two years, from August 2021 to August 2023. Key findings include:
- 38% of participants adhered to the program, as determined by completing the initial five sessions.
- 48% of these adherent users saw a significant reduction in symptoms within the first five sessions.
- 60% of those who finished all ten sessions achieved a meaningful decrease in symptom severity.
- There were notable reductions in pain, bloating, and IBS interference, along with improvements in bowel satisfaction.
Furthermore, a virtual symposium titled “Beyond Research: Bridging the Gap with Real World Results for Prescription Digital Therapeutics in IBS” is scheduled for November 3, 2023, to delve deeper into these findings and discuss the real-world implications of using Mahana IBS.